Stable suppository formulations effecting bioavailability of Ɗ⁹ -thc

Patent 5389375 Issued on February 14, 1995. Estimated Expiration Date:

May 21, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Method for effecting systemic delivery of delta-9-tetrahydrocannabinol Patent #: 4933363
Issued on: 06/12/1990
Inventor: ElSohly

Inventor

ElSohly, Mahmoud A.

Assignee

University of Mississippi

Application

No. 065117 filed on 05/21/1993

US Classes:

424/436, Anal, rectal (e.g., suppositories, etc.)514/966RECTAL

Examiners

Primary: Phelan, D. Gabrielle
Assistant: Azpuru, Carlos

Attorney, Agent or Firm

Morgan & Finnegan

International Class

A61F 009/02

Abstract

Suppository formulations having long-term stability and containing readily bioavailable Ɗ9 -THC derivatives.

Other References

ElSohy et al., Rectal Bioavailability of delta-9-tetrahydrocannabinol from various esters, Pharm Col. Biochem Behav., 40:497-502, 1991
ElSohy et al., Rectal bioavailable of Ɗ⁹ -tetrahydrocannabinol from the succinate ester in monkeys, Je Pharm. Sci., 80(10): 942-945, 199